In preclinical studies, enobosarm has been shown to increase muscle mass in the same muscles that support the bladder
Stress Urinary Incontinence (SUI), the involuntary loss of urine with physical activity occurs when the involved sphincter and support muscles become weak or do not function properly. These muscles lose their tone with age. Estrogen therapy (as part of Hormone Replacement Therapy, or HRT) in postmenopausal women can be helpful, but there is a concern with the use of estrogen therapy and the increased risk of uterine or breast cancer.
The muscles of the pelvic floor have a high number of androgen receptors and require hormone binding for optimal function. As the level of hormones produced by the ovaries decreases with age, these muscles can become atrophied.
In a Phase 2 proof-of-concept clinical trial of enobosarm in postmenopausal women with SUI, top-line results demonstrated that a daily dose of enobosarm 3 mg substantially improved SUI in women, as well as related quality of life measurements. Enobosarm has been shown, in preclinical work, to increase muscle mass in the same muscles responsible for SUI. The predominant SARM effect, in preclinical work, was on the levator ani muscle, the target for SUI muscle mass improvement.